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We sought to ascertain the long-term outcome and
genotype–phenotype correlations available for primary
hyperoxaluria type 1 in a large retrospective cohort study.
We examined the clinical history of 155 patients (129 families
primarily from Western Europe, North Africa, or the Middle
East) as well as the enzymatic or genetic diagnosis. The median
age at first symptom was 4 years, and at diagnosis 7.7 years,
at which time 43% had reached end-stage renal disease.
Presentations included: (1) early nephrocalcinosis and infantile
renal failure, (2) recurrent urolithiasis and progressive renal
failure diagnosed during childhood, (3) late onset with
occasional stone passage diagnosed in adulthood, (4) diagnosis
occurring on post-transplantation recurrence, and (5) family
screening. The cumulative patient survival was 95, 86, and 74%
at ages 10, 30, and 50 years, respectively, with the cumulative
renal survival of 81, 59, 41, and 10% at ages 10, 20, 30, and
50 years, respectively; 72 patients had undergone a total of 97
transplantations. Among the 136 patients with DNA analysis,
the most common mutation was p.Gly170Arg (allelic frequency
21.5%), with a median age at end-stage renal disease of
47 years for homozygotes, 35 years for heterozygotes, and
21 years for other mutations. Our results underscore the severe
prognosis of primary hyperoxaluria type 1 and the necessity
for early diagnosis and treatment, as well as confirm a better
prognosis of the p.Gly170Arg mutation.
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Primary hyperoxaluria type 1 (PH1, Online Mendelian
Inheritance in Man 259900) is an autosomal recessive
disorder caused by deficiency of the liver-specific, perox-
isomal, enzyme alanine: glyoxylate amino transferase (AGT),
involved in glyoxylate detoxification. AGT deficiency leads to
oxalate and glycolate overproduction.1 PH1 is a very rare
disease with an estimated prevalence ranging from 1 to 3 per
million population in Europe.2–4 PH1 can occur either
because AGT enzymatic activity is low, undetectable, or
because of AGTmistargeting to the mitochondria. As calcium
oxalate is poorly soluble in the urine, PH1 usually presents
with symptoms referable to the kidney and urinary tract,
such as stone formation and nephrocalcinosis. Both recurrent
renal stones and nephrocalcinosis can lead to progressive
renal impairment. Along with reduced oxalate excretion by
the kidneys as glomerular filtration rate progressively
declines, continued overproduction of oxalate leads to a
critical saturation point for plasma oxalate, and hence oxalate
deposition occurs in many organs, leading to systemic
involvement defined as oxalosis.5,6
The genetic basis for PH1 has been identified and
more than 100 mutations in the AGXT gene, coding
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AGT, have been published so far. In the Caucasian
population, two haplotypes have been defined, referred to
as minor and major allele, with a frequency of 20 and 80%,
respectively.7 The genotype–enzymatic phenotype correlation
is well known, whereas the clinical phenotype–genotype
correlation is more elusive. Thus, the effect of mutation
analysis on defining prognosis and therapeutic options is still
debated.
The diagnostic procedure has improved over the recent
years and can be based on reasonable recommendations.8,9
However, being rare, PH1 is still insufficiently known by
physicians, and diagnosis is often delayed.2,10 A significant
proportion of patients are only diagnosed once end-stage
renal disease (ESRD) has occurred or after disease recurrence
post renal transplantation (Tx).11,12 Considering the clinical
heterogeneity of PH1 and the lack of long-term available
data, more information is mandatory to understand better
the clinical course of the disease and to help define
therapeutic strategies and guidelines.
The objectives of this study are (1) to describe the long-
term clinical course in a cohort of PH1 patients and (2) to
extend the knowledge of associations between genotype and
clinical outcome.
RESULTS
Population characteristics
A total of 155 PH1 patients from 129 unrelated families were
identified. Diagnosis was made either by DNA analysis (79
patients), AGTenzyme activity in liver tissue (16 patients), or
both (57 patients). Another three patients, siblings of
confirmed PH1 patients, had clinical and biochemical
phenotype of PH1 and were included in the analysis. Male-
to-female ratio was 81/74 (1.09). Patients came from various
countries: a Caucasian origin was reported for 52%, Arab
origin (North Africa and Middle East) for 43%. A family
history of PH1 or nephrolithiasis was present in 56%, and
consanguinity in 46%.
Clinical features
Mean duration of follow-up since diagnosis was 7.0±8.7
years (median 3 years). Median age at first clinical
manifestation was 4.0 (interquartile range 0.6–8.1) years.
Symptoms occurred before 1 year of age in 40 patients (26%)
and after 15 years in 32 patients (21%). The median age at
diagnosis was 7.7 (interquartile range 2.0–27.9) years, at
which time 66 patients (43%) had reached ESRD. Mean time
between initial symptoms and diagnosis was 6.2±10.5 years
(median 1 year). In the 40 patients who were symptomatic
during infancy, mean diagnosis delay was 1.8 years (median 1
month). This mean delay was 8.0 years (median 3.5 years) for
the other patients. A total of 15 patients (10%) were
diagnosed after recurrence of oxalate deposition in the
transplanted kidney. Among the 20 patients (13%) who were
diagnosed by family screening, three were presymptomatic at
the time of diagnosis. The clinical features at the time of
diagnosis are summarized in Table 1.
Outcomes
Patient survival. Out of 155 patients, 20 died at a median
age of 19.9 (interquartile range 3.5–47.2) years. The
cumulative patient survival was 95, 86, and 74% at 10, 30,
and 50 years of age, respectively (Figure 1). In a multivariate
Cox regression analysis, the only factor significantly asso-
ciated with a higher risk of death (P¼ 0.007) was infantile
PH1 (hazard ratio (HR) 5.3, 95% confidence interval (CI)
1.6–18.2). Dialysis duration of more than 2 years was
predictive of a twofold increased risk of death, although the
association failed to be significant in a multivariate model
(P¼ 0.09).
Renal survival. Cumulative renal survival was 90, 81, 59,
41, and 10% at 1, 10, 20, 30, and 50 years of age, respectively
(Figure 2). The median survival without ESRD was 24 years
(CI 20–32). We subsequently performed subgroup analyses
according to geographic region, as a surrogate for access to
medical care. In patients living in the European Union
(N¼ 133), renal survival was 86, 62, and 49% at 10, 20, and
30 years, respectively. In the other regions (North Africa,
Middle East, and Brazil), 14 out of 22 patients presented with
Table 1 | Clinical characteristics of 155 PH1 patients at
diagnosis
Median (range) No. (%)
Total number of patients 155 (100)
Family history of PH1 57/129 (44)
Family history of urolithiasis 28/129 (22)
Age at first symptoms, years 4.0 (0.3–58.5) 142/155 (92)
History of recurrent urolithiasis 110/142 (77)
History of nephrocalcinosis 98/128 (76)
Age at clinical diagnosis, years 7.7 (0.3–67.0) 150/155 (97)
Age at definitive diagnosis, years 12.5 (0.4–73.3) 152/155 (98)
CKD 3–4 at diagnosis 109/150 (73)
ESRD at diagnosis 66/155 (43)
Extra-renal symptoms at diagnosisa 50/127 (39)
Abbreviations: CKD, chronic kidney disease; ESRD, end-stage renal disease; PH1,
primary hyperoxaluria type 1.
aIncluding oxalate osteopathy, retinopathy, skin deposits, oxalate cardiomyopathy,
and oxalate neuropathy (as reported spontaneously by clinicians).
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Figure 1 |Cumulative patient survival in 155 primary
hyperoxaluria type 1 patients.
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ESRD at the time of diagnosis, and renal survival was
50, 21, and 7% at age 10, 20, and 30 years, respectively.
Median age of survival without ESRD was significantly
different: 28 years (CI 21–35) in patients living in Europe
versus 9 years (CI 4–14) in others (P¼ 0.002). In a
multivariate Cox regression analysis, the presence of at least
one p.Gly170Arg allele was significantly associated with a
lower risk of ESRD (P¼ 0.005; HR 0.6, CI 0.4–0.9), whereas
infantile PH1 (P¼ 0.001; HR 6.0, CI 3.4–10.7) and low-
income region of residence (P¼ 0.006; HR 2.3, CI 1.3–4.1)
were associated with an increased risk of ESRD. Chronic
kidney disease (CKD) stage 3–4 at diagnosis did not remain a
statistically significant predictor of subsequent ESRD
(P¼ 0.10; HR 1.6, CI 0.9–2.4).
At last follow-up, 45 patients (33% of survivors) were on
conservative treatment, 62 (46%) had a functioning kidney
graft, and 28 (21%) were on dialysis.
Transplantation strategies. A total of 97 Tx (40 kidney Tx,
52 liver–kidney Tx, and 5 liver Tx) had been performed in
72 patients. Among the 29 patients who received an isolated
kidney Tx before eventual combined Tx, 26 grafts were
lost to oxalate deposition in the kidney in 24 patients (83%)
and two were lost to other causes (7%). The median time
between the first isolated kidney Tx and graft loss was 11
months (range 1 day–12.8 years). One patient received a pre-
emptive isolated liver Tx at 5 years of age,13 but reached
ESRD because of a combination of nephrotoxicity and
nephrocalcinosis parenchymal injury, leading to further
kidney transplant at 16 years after liver Tx. A total of 52
patients received a combined liver–kidney Tx (11 subse-
quently to a previous isolated kidney Tx). After 5 years of
median follow-up (range 2 days–15.7 years), 34 (65%) had
functioning liver and kidney grafts. Kidney graft failure
occurred in nine cases (17%), liver graft failure in 10 (19%),
and 11 deaths were reported (seven of whom within 3
months after Tx).
Infantile PH1. Among the 40 patients with infantile form,
29 (72%) presented with nephrocalcinosis and 19 (47%)
experienced ESRD at the time of diagnosis. Seven (18%) have
died during follow-up. The cumulative incidence of ESRD in
this group was 50% at 3 years of age, 63% at 10 years, and
85% at 20 years. Details of infantile forms by genotype are
reported in Table 2.
Mutation analysis
DNA analysis was performed in 140 patients from 116
families. A minimum of one mutation was identified in 136
patients (Tables 3 and 4). A total of 222 mutations out of 232
expected alleles (116 families) were observed, corresponding
to a detection rate of 95%. In all, 52 different mutations were
identified. The p.Gly170Arg mutation (c.508G4A) was
found in 36 patients (26%), of whom 24 were compound
heterozygous and 12 homozygous (allelic frequency: 21.5%).
The p.Ile244Thr mutation (c.731T4C) was detected in 27
patients (20%) with an allelic frequency of 21%. In all, 16
patients (12%) in 15 families (allelic frequency: 9.5%) carried
the c.33dupC mutation and 7 patients (5%) the p.Phe152Ile
mutation (c.454T4A). The p.Arg122Stop mutation
(c.486C4T) was found in a homozygous state in 5 of 10
patients (7 families) from Lebanon. The majority of the
remaining mutations were private mutations. There was
marked intra- and inter-familial phenotypic heterogeneity in
families with private mutations from ESRD in infancy to
PH1 diagnosed in the second or third decade of life.
Genotype–phenotype correlations
p.Gly170Arg mutation. In patients who were homo- or
heterozygous for the p.Gly170Arg mutation, 8/12 (67%)
homozygous patients and 16/24 (67%) heterozygous devel-
oped ESRD, which is similar to 68/100 (68%) in patients with
other mutations. However, ESRD was delayed in p.Gly170Arg
patients, for which the median age at ESRD was 47 years (CI
43–50) in homozygotes and 35 years in heterozygotes,
compared with 21 years in patients without p.Gly170Arg
mutation (Figure 3). The cumulative survival free from ESRD
was significantly different according to the p.Gly170Arg
genotyping (log-rank test: P¼ 0.02). Among the 12 patients
who were homozygous for the p.Gly170Arg mutation, six
were diagnosed when ESRD had been reached, and another
already had CKD stage 3. Renal function was preserved over
time in all five homozygous patients without CKD at
diagnosis. One homozygous patient experienced early
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Figure 2 |Cumulative survival free from end-stage renal
disease (ESRD) in 155 primary hyperoxaluria type 1
patients.
Table 2 | Characteristics of infantile cases of PH1 by genotype
Most
common
mutations
No. of patients with
symptoms before 1 year
(N=40) (homozygous/
heterozygous)
No. of patients with ESRD
reached before 1 year (N=17)
(homozygous/heterozygous)
p.Gly170Arg 6 (1/5) 2 (0/2)
p.Ile244Thr 10 (6/4) 3 (2/1)
c.33dupC 3 (1/2) 2 (1/1)
p.Arg122Stop 4 (4/0) 2 (2/0)
p.Phe152Ile 2 (0/2) 2 (0/2)
p.Glu82Gln 2 (2/0) 1 (1/0)
Abbreviations: ESRD, end-stage renal disease; PH1, primary hyperoxaluria type 1.
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isolated nephrocalcinosis and presented with an infantile
form of PH1 (Table 2).
p.Ile244Thr mutation. In the p.Ile244Thr group, ESRD
was reached in 11/20 homozygous patients and in 3/7
heterozygotes (including one compound heterozygote,
p.Gly170Arg/p.Ile244Thr). The median age at ESRD was
33 years (CI 27–46) for p.Ile244Thr homozygous patients
(four of whom reached ESRD by age 2), 34 years in
heterozygotes, whereas it was 23 years for others. The
cumulative survival free from ESRD was not different
according to p.Ile244Thr genotyping (log-rank test:
P¼ 0.88). When comparing the survival free from ESRD
among the three groups, homozygosity for p.Gly170Arg, or
p.Ile244Thr mutation and other genotypes (Figure 4), the
difference did not reach statistical significance (log-rank test:
P¼ 0.12).
p.Phe152Ile mutation. Only one patient was homozygous
for p.Phe152Ile. He had been symptomatic since 24 years of
age and was clinically diagnosed as PH1 at age 49, reaching
ESRD at 74.5 years. Six compound heterozygous patients
with one allele with the p.Phe152Ile mutation reached ESRD
at a median age of 27.5 years (range 0.3–58.1). Pyridoxine
sensitivity was neither formally tested nor reported in these
patients.
c.33dupC mutation. A total of five patients were homo-
zygous for the c.33dupC. mutation, coding for a truncated
protein, and three of them had had symptoms before 1 year
of age. Among the five homozygous patients, two still had
preserved renal function at 1 and 19 years of age, and three
had reached ESRD at 3 months, 10, and 23 years of age. Two
siblings of the latter with no DNA analysis had infantile form
and reached ESRD at 8 months and 5 years of age.
Genotype–enzyme activity correlation. A total of 82
patients had liver AGT activity measured. Of these, 18 had
AGT activity above 10% of normal activity and 14 of these
18 patients had at least one p.Gly170Arg. allele (no
genotyping in two patients, one patient was homozygous
for p.Ile244Thr, and one for Gly82Glu). In the 5/12
p.Gly170Arg homozygotes with AGT measured, median
AGT activity was 41% (range 12–50). In the 14/25 patients
heterozygous for p.Gly170Arg with AGT activity measured,
median AGT activity was 14% (range 3–28). Thus, it seems
Table 3 | Percentage of the most common mutations
identified from 222 alleles
Mutation
No. of patients
(homozygous/
heterozygous)
Allele
frequency
(%)
Origin of
patients (%)
p.Gly170Arg 36 (12/24) 21.5 Western Europe (97%)
p.Ile244Thr 27 (20/7) 21 North Africa (93%)
c.33dupC 16 (5/11) 9.5 Various countries
p.Arg122Stop 5 (5/0) 4.5 Middle East (100%)
p.Phe152Ile 7 (1/6) 3.5 Western Europe (100%)
Others 45 40 Various countries
Table 4 | Repartition of the most common mutations
identified from 136 patients
Mutation
Total no.
of patients
(H/h)
No. of patients
from France
(H/h)
No. of patients
from other
countries (H/h)
p.Gly170Arg 36 (12/24) 27 (7/20) 9 (5/4)
p.Ile244Thr 27 (20/7) 22 (18/4) 5 (2/3)
c.33dupC 16 (5/11) 10 (3/7) 6 (2/4)
p.Arg122Stop 5 (5/0) 1 (1/0) 4 (4/0)
p.Phe152Ile 7 (1/6) 6 (1/5) 1 (0/1)
Abbreviation: H/h, homozygous/heterozygous.
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Figure 3 |Cumulative survival free from ESRD according to
genotyping for p.Gly170Arg mutation in 136 primary
hyperoxaluria type 1 patients.
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that patients with higher AGT activity belong to the group
with better renal survival.
DISCUSSION
The clinical data and genotypes of a large multiethnic cohort
of proven PH1 patients are presented in this study. Our data
contribute to better delineate the long-term spectrum
of PH1.
As previously reported,5 PH1 could be classified into one
of the five presentations: (1) an infantile form with early
nephrocalcinosis and renal failure (26%), (2) a recurrent
urolithiasis and progressive renal failure leading to diagnosis
in adolescence or early adulthood (30%), (3) a late-onset
form with occasional stone passage leading to diagnosis in
adulthood (21%), (4) a diagnosis occurring on post-
transplantation recurrence (10%), and (5) a diagnosis made
by family screening (13%). Nephrolithiasis and nephrocalci-
nosis were the first manifestations of the disease in most
patients, confirming that all patients with recurrent kidney
stones or nephrocalcinosis should be screened for PH1. This
can be carried out by determination of either urinary oxalate
and glycolate excretion on 24 h urine examination or on
repeated urine samples, or, in patients with ESRD, plasma
oxalate and glycolate concentrations.6,8 Crystalluria analysis
and accurate analysis of the morphology and composition of
stones may also yield useful information.14,15 Approximately
40% of patients had both ESRD and extra-renal symptoms at
the time of diagnosis, and the proportion increased to 60% in
patients diagnosed during adulthood. Moreover, a substantial
proportion of adult patients were diagnosed after oxalosis
recurrence following isolated kidney Tx. The fact that most
adult patients diagnosed had already developed ESRD may
have several reasons: (1) urolithiasis caused by inborn errors
of metabolism are still unknown or underestimated by
physicians, (2) symptoms precluding renal failure may be
mild in case of PH1, and (3) the only diagnosis available for
PH1 was once invasive and potentially harmful after anuria
had occurred and urine oxalate assessment was no longer
available. We therefore believe that screening for PH1 should
be performed in all ESRD of unknown origin in case of
personal or familial history of urolithiasis or nephrocalci-
nosis. Presence of systemic oxalosis and increased level of
plasma oxalate (usually480 mmol/l in ESRD) provide valu-
able clues indicative of the necessity for diagnosis confirma-
tion by oriented genetic testing or enzymatic diagnosis.
PH1 is a life-limiting condition. Mortality rate was 28% in
the Swiss cohort3 and 19% in the Dutch cohort.4 The overall
death rate due to PH1 or its treatment in our series was 13%.
The only predictive factor for death was infantile PH1, which
often presents as a life-threatening condition because of a
rapid progression to ESRD as a result of a combination of
early oxalate load and immature glomerular filtration rate.16
Infantile oxalosis is a frequent cause of early ESRD in some
developing countries where therapeutic withdrawal can be
regarded as an acceptable option.16 Conversely, the prognosis
may be excellent in developed countries where combined
liver–kidney Tx is available.17 Although not statistically
significant, patients on maintenance dialysis for more than
2 years were also at a higher risk of death. Because dialysis
does not stop the formation or removes oxalate deposits,
PH1 patients may die from complications of systemic
oxalosis. This stresses the importance of planning either
pre-emptive or at least early combined liver–kidney Tx in
PH1 patients while maintaining intensive dialysis.18,19
In this study, the median time to ESRD since birth was 24
years. Early studies reported that 50% of patients developed
ESRD by 15 years and 80% by 30 years of age.20 The recent
improvements in diagnosis procedure and PH1 management
have delayed the median survival without ESRD to 33 years.10
The shorter time to ESRD observed in this study might be
because of a greater proportion of patients with ESRD at the
time of diagnosis, compatible with both delayed diagnosis
and management. It should be noted that, in this study, all
patients who were formally diagnosed in France were
included as well as a number of patients who came from
countries with lower access to medical care.
In a multivariate analysis, we found that both infantile
PH1 and the presence of p.Gly170Arg mutation were
significantly associated with renal outcome, in opposite ways.
Infantile onset of PH1 was the main predictor of progression
to ESRD: 50% of affected infants experienced ESRD by the
age of 3 years and two-thirds reached ESRD by 10 years of
age. The presence of CKD stage 3–4 at the time of diagnosis
was only a predictor of borderline significance for subsequent
ESRD. Indeed, most patients with a glomerular filtration rate
460ml/min per 1.73m2 at the time of diagnosis did not
reach ESRD during follow-up. These data suggest that timely
diagnosis and treatment at a stage of preserved renal function
may modify the course of the disease. An aggressive
conservative treatment of PH1 patients with high fluid
intake (2–3 l/m2) orally, or enterally using nasogastric tube or
gastrostomy placement, calcium oxalate crystallization in-
hibitors, and pyridoxine may improve renal survival. These
treatments should therefore be started as soon as the
diagnosis of PH1 has been considered.21–23
Our results also provide clinical evidence that the
p.Gly170Arg mutation is associated with a better renal
outcome even after adjustment for potential confounding
variables. We found that patients homozygous for the
p.Gly170Arg, and also heterozygous ones, experienced a
delayed progression to ESRD, and that homozygous patients
without ESRD at diagnosis have a preserved renal function
during follow-up. The p.Gly170Arg mutation is the most
common one in the European and North American
population, and results in the singular AGT mistargeting
from peroxisome-to-mitochondria. Although the mechanism
is still unclear, pyridoxine decreases urinary excretion of
oxalate in some patients. To date, response to pyridoxine has
mostly been shown in patients with the p.Gly170Arg
mutation and is suggested for the p.Phe152Ile mutation.24–26
However, it is unknown whether pyridoxine responsiveness
allows maintenance of a stable renal function over time, and
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does not just delay the onset of ESRD. As pyridoxine
treatment and responsiveness were not systematically re-
corded in our cohort, this remains to be analyzed. The fact
that homozygous patients for p.Gly170Arg still reach ESRD
might be attributed to late diagnosis and treatment as well as
pre-existing renal lesions. No conclusions could be drawn for
the p.Phe152Ile mutation as the number of patients was too
small. The only other genotype that could be analyzed was
the p.Ile244Thr mutations, which was highly prevalent in our
study because of the great number of patient coming
from Arab countries. No difference could be detected in that
group one way or another. The c.33dupC mutation, although
rare, was found in patients with both severe and less severe
form of the disease, unlike previous reports.25 Thus, the
individual clinical benefit of mutation analysis, excluding its
role in diagnosis, might still be debated.27,28 Indeed,
genotyping may be useful for prognosis in a population
but should be interpreted with caution in individuals for
several reasons; in addition to the large number of private
mutations, most patients with PH1 are compound
heterozygotes and there is a marked intrafamilial clinical
heterogeneity in some pedigrees, suggesting a role for
modifier genes.
Our data also confirm the poor graft survival and patient
quality of life of isolated renal Tx. Previous studies have
reported a renal graft survival ranging from 17 to 23% at
3 years to 48% at 8 years after Tx.29,30 Therefore, we cannot
recommend isolated kidney transplantation for PH1 patients
except as a temporary solution in some countries before
managing the patient in a specialized center for further liver
or combined liver–kidney Tx and the possible exception of
pyridoxine-sensitive patients.
Our study has some limitations. This is a retrospective
study and some patients have been lost to follow-up. Data
that may have an influence on renal outcome—such as
urinary oxalate and pyridoxine response—were not reported
in some patients. We should also not dismiss the possibility
of a selection bias: patients referred for genotyping may be
those with the more severe course and may not represent the
true spectrum of the disease in the general population.
CONCLUSION
We have shown in this study that mutation analysis may be
clinically useful for PH1 patients, as the homozygous p.
Gly170Arg mutation is associated with a better prognosis,
although careful consideration should be given to therapeutic
strategy. Mutation analysis is an important diagnostic tool in
patients with severe hyperoxaluria when dialysis or trans-
plantation is considered. With the constitution of a European
hyperoxaluria consortium (www.oxaleurope.com) and future
collaboration with the Mayo Clinic registry, several hundred
PH1 cases will be available for genotype–phenotype correla-
tion studies. Collection of a large cohort of families and
subsequent careful analysis may be the handle needed to
tackle the problem of genetic and environmental modifiers at
the root of the variability of disease expression.
MATERIALS AND METHODS
Subjects and data collection
The study design is that of a retrospective cohort of patients with
PH1 diagnosed between 1993 and 2008. PH1 was defined on the
following criteria: AGT enzyme activity below 50% on liver biopsy,
or mutations on AGXT gene, or urinary biochemistry in favor of
PH1 in siblings of enzymatically or genetically proven PH1 patients.
Enzymatic studies and mutation analysis were performed in the
same reference laboratory in Lyon, France.
Clinical and laboratory informations were collected on chart
review or provided by questionnaires sent to physicians. Clinicians
in charge of PH1 patients who did not respond were personally
approached by the researchers. Baseline characteristics, such as sex,
ethnic origin, family history of urolithiasis or PH1, and consangui-
nity, were recorded, as well as clinical presentation and renal
outcome (urolithiasis, nephrocalcinosis, dialysis, and Tx). Data
regarding conservative treatment were not systematically recorded.
Extra-renal symptoms were not systematically collected but
spontaneously reported by clinicians. Laboratory data included
plasma creatinine levels, AGXTmutations, and AGTenzyme activity.
Renal function was estimated by the Schwartz formula in children
and the Cockcroft formula in adults.31,32 CKD was defined as a
glomerular filtration rate o60ml/min per 1.73m2, that is, Kidney
Disease Outcome Quality Initiative stage 3 and 4 CKD.33 Infantile
PH1 was defined as PH1 becoming symptomatic before the
age of 1 year.
DNA analysis
DNA of the patients was extracted from whole blood using
conventional methods. According to French law, DNA samples
were obtained with an informed consent for genetic analysis. The 11
exons and exon–intron boundaries of the AGXT gene were amplified
from genomic DNA using standard PCR procedures with in-house-
designed primers. Direct bidirectional sequencing of purified PCR
products was performed using the BigDye Terminator v3.1
Sequencing Kit (Applied Biosystems, Foster City, CA, USA) and
an ABI 3730 genetic analyzer. Sequences were analyzed using
Seqscape Analysis Software (Applied Biosystems) in comparison
with GeneBank Reference genomic sequence (NT_005416).
The mutation nomenclature used in this work follows the
guidelines of Human Genome Variation Society (http://www.
hgvs.org) and the DNA mutation numbering is based on the cDNA
reference sequence (GeneBank accession number NM_000030.2).
Each novel missense sequence alteration was screened in 100 control
alleles. For the patients with suspicion of large deletion, real-time
quantitative PCR was performed using Light Cycler technology
(Roche Applied Science, Manheim, Germany).
Statistical analysis
Results were expressed as median and interquartile range or
mean±s.d. for continuous variables, and as percentage for
categorical variables. Patient and renal survival from birth were
estimated using a time-to-failure Kaplan–Meier method. The end
point for renal survival was defined as start of dialysis or first renal
Tx. Data were censored at the time of death due to ESRD or last
available follow-up. Factors associated with patient and renal
survival were estimated by univariate and multivariate analyses
using Cox’s proportional hazard model. The age at diagnosis was
considered to be that of initiation of specific management even if
enzymatic or genetic confirmation was performed later. Log-rank
test was used for comparison between subgroups. A P-value o0.05
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was considered statistically significant. All statistical analyses
were carried out using SAS software (version 8.2; SAS Institute,
Cary, NC, USA).
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